Professional Documents
Culture Documents
Coronary Artery Disease
Coronary Artery Disease
PATIENTS WITH
CORONARY
VASCULAR
DISORDERS
Coronary Artery Disease
Layers
of the
Artery
Arteriosclerosis
- A diffuse process whereby the muscle fibers and
the endothelial lining of the walls of
arteries/arterioles become thickened
- “Hardening of the arteries”
- Due to chronic smoking
Atherosclerosis
- A progressive and reversible atherosclerosis
affecting the intimal
RISK FACTORS
• Increasing age
• Gender (Men develop
CAD at an earlier stage
Non-modifiable than women)
• Family history of CAD • Race (Higher incidence
in African Americans)
Modifiable • Diabetes
• Hyperlipidemia • Metabolic syndrome
• Cigarette smoking • Obesity
(tobacco use) • Physical inactivity
• Hypertension
PATHOPHYSIOLOGY
Accumulation of lipids/fatty
streaks in the intima of
coronary artery
↓
Macrophages ingest the
lipids and die
↓
Proliferation of smooth
muscle cells forming a
fibrous cap
↓
Development of
atheroma or fibrous
plaque
↓
Degenerative
changes in the
arterial wall
• Narrowing of the lumen
• Increased resistance to blood
flow
• Thrombus formation
↓
Decreased blood flow to the
myocardium
↓
Myocardial
ischemia
↓
Angina Pectoris
↓
MYOCARDIAL INFARCTION
Clinical Manifestations: • Angina –
classic sign of CAD
• Diaphoresis, cool
extremities
Medical Management:
Goals:
• Decrease myocardial oxygen
demand/cardiac workload
• Increase oxygen supply to the
myocardium
• Alleviate chest pain
• Anticoagulant
• Antilipemics
• Thrombolytics
NUTRIENT CONTENT OF
THE THERAPEUTIC
LIFESTYLE
CHANGES (TLC) DIET
Nutrient Recommended Intake
Total Calories Balance intake and
expenditure to maintain
desirable weight
Total fat 25-35% of calories
Saturated fat <7% of calories
Polyunsaturated fat Up to 10% of total calories
Monounsaturated fat Up to 20% of total calories
Carbohydrates 50-60% of total calories
Dietary fiber 20-30 g/day
Protein Approximately 15% of
total calories
Cholesterol <200 mg/day
ANTILIPIDEMIC AGENTS
HMG-COA
REDUCTASE
INHIBITORS (STATINS)
(HMG-CoA – 3 hydroxy-3
• Atorvastatin (Lipitor) • methylglutaryl coenzyme A)
Simvastatin (Zocor) involved in the lipid
synthesis.
• They inhibit the enzyme
• Myalgia and arthralgia are • Monitor liver function tests
common adverse effects
CHOLESTEROL
ABSORPTION INHIBITOR
• Ezetimibe (Zetia) • Decrease LDLs
• Inhibits absorption of
cholesterol in the small
intestine.
• Used in combination with
statins.
• Contraindicated in liver
disease
Surgeries
• Coronary Artery Bypass Graft (CABG)
• Percutaneous Transluminal Coronary
Angioplasty (PTCA)
• Laser Angioplasty
Nursing Management:
• Initiating primary and secondary
prevention
•
Tobacco Use
• Hypertension
• DM
• Weight Reduction
• Diet Modification
• Exercise Programs